Company Monitoring Page for Eisai

latest headlines for company on cafepharma

Eisai hands off responsibility for Aduhelm to Biogen
Pharmaforum
Tue, 03/15/22 - 11:43 am
Tags:
Eisai, Biogen, Aduhelm, Alzheimer's disease
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Fierce Biotech
Mon, 02/14/22 - 12:05 pm
Tags:
Hemavant, Roivant Sciences, Eisai, MDS, RVT-2001
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Thu, 02/10/22 - 10:16 am
Tags:
Eisai, Biogen, Aduhelm, Alzheimer's disease, FDA, CMS
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
Tags:
FDA, adagrasib, donanemab, faricimab, lecanemab, tezepelumab, tirzepatide, vutrisiran, Eli Lilly, Mirati Therapeutics, Roche, Chugai, Eisai, Biogen, AstraZeneca, Amgen, Alnylam
Biogen and Eisai move forward with investigational Alzheimer's therapy
Biopharma Reporter
Mon, 01/3/22 - 10:45 pm
Tags:
Biogen, Eisai, lecanemab, Alzheimer's disease, fast track, FDA
Biopharma developments over the Christmas period
EP Vantage
Mon, 01/3/22 - 10:26 am
Tags:
Alnylam Pharmaceuticals, Bio-Thera Solutions, BioArctic, Biogen, BridgeBio Pharma, Daiichi Sankyo, Eisai, JNJ, Madrigal Pharmaceuticals, Merck, Sutro BioPharma, Tasly Pharmaceutical Group
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA
Fierce Biotech
Tue, 12/28/21 - 10:55 am
Tags:
Biogen, Eisai, lecanemab, FDA, Aduhelm, fast track, Alzheimer's disease
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
Fierce Pharma
Wed, 12/22/21 - 11:06 am
Tags:
Biogen, Eisai, Aduhelm, Japan, Alzheimer's disease
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
Tags:
licensing, GSK, Alector, Novartis, BeiGene, Pfizer, Arvinas, iTeos Therapeutics, Bristol Myers Squibb, Eisai
Eisai-Biogen Alzheimer's Drug Shows Amyloid Reduction, Disease-Modifying Effect
BioSpace
Thu, 11/11/21 - 10:55 am
Tags:
Eisai, Biogen, lecanemab, Alzheimer's disease, clinical trials
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Tags:
Novartis, M&A, Roche, Sandoz, Aurinia Pharmaceuticals, Alnylam, Exelixis, Incyte, Eisai, Genmab
Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s
Pharmaforum
Wed, 10/20/21 - 10:08 am
Tags:
Altoida, Eisai, clinical trials, augmented reality, Alzheimer's disease
Seizing Aduhelm precedent, Biogen, Eisai get the ball rolling on another accelerated Alzheimer's approval
Endpoints
Tue, 09/28/21 - 12:07 am
Tags:
Biogen, Aduhelm, Eisai, Alzheimer's disease, FDA, lecanemab
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
Mon, 08/23/21 - 11:10 am
Tags:
FDA, Cara Therapeutics, Vifor Pharma, Korsuva, Kadmon, belumosudil, Bristol Myers Squibb, Opdivo, Merck, Eisai, Keytruda
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Thu, 08/12/21 - 12:35 pm
Tags:
Merck, Keytruda, advanced renal cell carcinoma, renal cell carcinoma, Eisai, Lemvima, FDA
Biogen, Eisai are pushing for another accelerated Alzheimer's OK — this time for BAN2401
Endpoints
Wed, 08/4/21 - 10:55 am
Tags:
Biogen, Eisai, FDA, Alzheimer's disease, BAN2401
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg
Thu, 07/15/21 - 10:45 am
Tags:
Biogen, Eisai, Alzheimer's disease, lecanemab, BAN2401
Eisai-Biogen Alzheimer’s drug gets FDA breakthrough designation
Pharmaceutical Business Review
Thu, 06/24/21 - 10:56 am
Tags:
Eisai, Biogen, FDA, lecanemab, breakthrough status, Alzheimer's disease
Bristol Myers pays $650M for rights to Eisai's phase 1 ADC
Fierce Biotech
Fri, 06/18/21 - 10:11 am
Tags:
Bristol Myers Squibb, antibody-drug conjugate, MORAb-202, Eisai
Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
Reuters
Thu, 06/17/21 - 10:56 pm
Tags:
Bristol Myers Squibb, Eisai, drug development, cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.